Talphera (NASDAQ:TLPH – Get Free Report) and IM Cannabis (NASDAQ:IMCC – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.
Valuation & Earnings
This table compares Talphera and IM Cannabis”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Talphera | $1,000.00 | 56,318.01 | -$14.29 million | ($0.27) | -4.02 |
| IM Cannabis | $39.17 million | 0.03 | -$8.10 million | ($60.66) | -0.02 |
Profitability
This table compares Talphera and IM Cannabis’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Talphera | N/A | -87.28% | -51.36% |
| IM Cannabis | -39.62% | N/A | -58.32% |
Institutional and Insider Ownership
37.7% of Talphera shares are held by institutional investors. Comparatively, 7.7% of IM Cannabis shares are held by institutional investors. 3.5% of Talphera shares are held by insiders. Comparatively, 5.9% of IM Cannabis shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Volatility & Risk
Talphera has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500. Comparatively, IM Cannabis has a beta of 2.21, indicating that its stock price is 121% more volatile than the S&P 500.
Analyst Ratings
This is a summary of recent recommendations and price targets for Talphera and IM Cannabis, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Talphera | 1 | 1 | 2 | 0 | 2.25 |
| IM Cannabis | 1 | 0 | 0 | 0 | 1.00 |
Talphera presently has a consensus price target of $3.00, indicating a potential upside of 176.50%. Given Talphera’s stronger consensus rating and higher possible upside, equities analysts clearly believe Talphera is more favorable than IM Cannabis.
Summary
Talphera beats IM Cannabis on 8 of the 14 factors compared between the two stocks.
About Talphera
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.
About IM Cannabis
IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.
Receive News & Ratings for Talphera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talphera and related companies with MarketBeat.com's FREE daily email newsletter.
